Platelet glycoprotein IIb/IIIa receptor inhibitors in cardiovascular disease

In Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease, the major investigators working in this rapidly advancing field join together under the aegis of A. Michael Lincoff and Eric J. Topol to provide the first comprehensive overview of the preclinical and clinical development of the glycoprotein IIb/IIIa receptor antagonists. These acknowledged experts elucidate the theoretical basis for the inhibition of platelet aggregation in the treatment of coronary syndromes, present and synthesize evidence for the efficacy of glycoprotein IIb/IIIa blockade in inhibiting ischemic complications of both coronary intervention and acute coronary syndromes, and provide guidelines for the use of this novel class of agents in the clinical management of cardiovascular disease. They also compare the pharmacology and clinical efficacy of the currently available glycoprotein IIb/IIIa receptor inhibitors and speculate about further potential applications of these agents in the treatment of vascular disease. Written by the scientists and physicians who discovered and characterized this important new class of receptors, invented the first IIb/IIIa agents, and conducted the definitive clinical trials, Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease offers the most complete and authoritative review of these powerful new therapeutics available today. Front Matter....Pages i-xiv Front Matter....Pages 1-1 Thrombosis in Acute Coronary Syndromes and Coronary Interventions....Pages 3-20 Mechanisms of Platelet Adhesion....Pages 21-34 Glycoprotein IIb-IIIa in Platelet Aggregation and Acute Arterial Thrombosis....Pages 35-66 Glycoprotein IIb/IIIa Antagonists: Development of Abciximab and Pharmacology of Select Agents....Pages 67-89 Front Matter....Pages 91-91 Abciximab During Percutaneous Coronary Intervention — The EPIC, EPILOG, and EPISTENT Trials....Pages 93-113 Eptifibatide in Coronary Intervention—The IMPACT Trials....Pages 115-126 Tirofiban in Coronary Intervention—The RESTORE Trial....Pages 127-142 The Use of Abciximab in Therapy Resistant Unstable Angina....Pages 143-168 Overview of the Glycoprotein IIb/IIIa Inhibitor Interventional Trials....Pages 169-197 Front Matter....Pages 199-199 Unstable Angina: PARAGON, PURSUIT, PRISM, and PRISM-PLUS....Pages 201-227 The Use of Glycoprotein IIb/IIIa Inhibition in Acute Myocardial Infarction....Pages 229-249 Front Matter....Pages 251-251 Economics of Glycoprotein IIb/IIIa Inhibition....Pages 253-266 Monitoring Platelet Aggregation....Pages 267-285 Oral Platelet Glycoprotein IIb/IIIa Blockade....Pages 287-314 Cerebrovascular Aspects of Glycoprotein IIb/IIIa Inhibitors....Pages 315-326 The Future of Glycoprotein IIb/IIIa Inhibitors....Pages 327-360 Back Matter....Pages 361-369